Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 236

1.

Improving the clinical risk score: an analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases.

Maithel SK, Gönen M, Ito H, Dematteo RP, Allen PJ, Fong Y, Blumgart LH, Jarnagin WR, D'Angelica MI.

Surgery. 2012 Feb;151(2):162-70. doi: 10.1016/j.surg.2011.07.020. Epub 2011 Oct 6.

PMID:
21982065
2.

Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.

Kim SH, Kwon HC, Oh SY, Lee DM, Lee S, Lee JH, Roh MS, Kim DC, Park KJ, Choi HJ, Kim HJ.

Am J Clin Oncol. 2009 Feb;32(1):38-43. doi: 10.1097/COC.0b013e31817be58e.

PMID:
19194123
3.

Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer.

Corsi DC, Ciaparrone M, Zannoni G, Mancini M, Cassano A, Specchia M, Pozzo C, Martini M, Barone C.

Eur J Cancer. 2002 Mar;38(4):527-34.

PMID:
11872345
4.

Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.

Kobayashi H, Sugihara K, Uetake H, Higuchi T, Yasuno M, Enomoto M, Iida S, Azuma M, Mori R, Omori A, Lenz HJ, Danenberg KD, Danenberg PV.

Int J Oncol. 2008 Dec;33(6):1257-62.

PMID:
19020759
5.

[Prognostic factors for long-term outcome of hepatic resection for colorectal liver metastases].

Aldrighetti L, Castoldi R, Di Palo S, Arru M, Stella M, Orsenigo E, Gavazzi F, Ferla G, Di Carlo V, Staudacher C.

Chir Ital. 2005 Sep-Oct;57(5):555-70. Italian.

PMID:
16241086
6.

Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.

Ciaparrone M, Quirino M, Schinzari G, Zannoni G, Corsi DC, Vecchio FM, Cassano A, La Torre G, Barone C.

Oncology. 2006;70(5):366-77. Epub 2006 Dec 15.

PMID:
17179731
7.

Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution.

House MG, Ito H, Gönen M, Fong Y, Allen PJ, DeMatteo RP, Brennan MF, Blumgart LH, Jarnagin WR, D'Angelica MI.

J Am Coll Surg. 2010 May;210(5):744-52, 752-5. doi: 10.1016/j.jamcollsurg.2009.12.040.

PMID:
20421043
8.

Does neoadjuvant chemotherapy reveal disease precluding surgical treatment of initially resectable colorectal cancer liver metastases?

Reddy SK, Tsung A, Marsh JW, Geller DA.

J Surg Oncol. 2012 Jan;105(1):55-9. doi: 10.1002/jso.22044. Epub 2011 Aug 12.

PMID:
21842519
9.

Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: implications for chemotherapeutic options and survival.

Bathe OF, Franceschi D, Livingstone AS, Moffat FL, Tian E, Ardalan B.

Cancer J Sci Am. 1999 Jan-Feb;5(1):34-40.

PMID:
10188059
10.

The clinical value of hepatocyte growth factor and its receptor--c-met for liver cancer patients with hepatectomy.

Wu F, Wu L, Zheng S, Ding W, Teng L, Wang Z, Ma Z, Zhao W.

Dig Liver Dis. 2006 Jul;38(7):490-7. Epub 2006 Apr 14.

PMID:
16627020
12.

Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection.

Maithel SK, Coban I, Kneuertz PJ, Kooby DA, El-Rayes BF, Kauh JS, Sarmiento J, Staley CA 3rd, Volkan Adsay N.

Ann Surg Oncol. 2011 Sep;18(9):2699-705. doi: 10.1245/s10434-011-1610-x. Epub 2011 Mar 1.

PMID:
21360249
13.

[Prediction of the efficacy of modified FOLFOX6 therapy according to the mRNA levels of thymidylate synthase (TS), excision repair cross-complementing-1 and -2( ERCC-1 and ERCC-2) and methylenetetrahydrofolate dehydrogenase( MTHFD) in the primary lesion of colorectal cancer].

Ishibashi K, Okada N, Tajima Y, Ishiguro T, Kuwabara K, Ohsawa T, Kumamoto K, Tsuji Y, Haga N, Iwama T, Ishida H, Onouchi T, Yakabi K.

Gan To Kagaku Ryoho. 2011 Nov;38(12):2220-3. Japanese.

PMID:
22202336
14.

Effect of hepatocyte growth factor on progression of liver metastasis in colorectal cancer.

Osada S, Matsui S, Komori S, Yamada J, Sanada Y, Ihawa A, Tanaka Y, Tokuyama Y, Okumura N, Nonaka K, Hosono Y, Takahashi T, Yamaguchi K, Yoshida K.

Hepatogastroenterology. 2010 Jan-Feb;57(97):76-80.

PMID:
20422876
15.

[Study on the prognostic value of hepatocyte growth factor and c-met for patients with hepatocellular carcinoma].

Wu FS, Zheng SS, Wu LJ, Ding W, Ma ZM, Wang ZM, Teng LS, Zhao WH.

Zhonghua Wai Ke Za Zhi. 2006 May 1;44(9):603-8. Chinese.

PMID:
16784653
16.

Survival outcomes of patients with colorectal liver metastases following hepatic resection or ablation in the era of effective chemotherapy.

Nikfarjam M, Shereef S, Kimchi ET, Gusani NJ, Jiang Y, Avella DM, Mahraj RP, Staveley-O'Carroll KF.

Ann Surg Oncol. 2009 Jul;16(7):1860-7. doi: 10.1245/s10434-008-0225-3. Epub 2008 Nov 27.

PMID:
19037703
17.

P53 overexpression in colorectal metastases confined to the liver and outcome of liver resection.

Heisterkamp J, van Bommel J, Hop WC, Tilanus HW, Zondervan PE, IJzermans JN.

Hepatogastroenterology. 1999 Nov-Dec;46(30):3109-14.

PMID:
10626170
18.

Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.

Righi L, Papotti MG, Ceppi P, Billè A, Bacillo E, Molinaro L, Ruffini E, Scagliotti GV, Selvaggi G.

J Clin Oncol. 2010 Mar 20;28(9):1534-9. doi: 10.1200/JCO.2009.25.9275. Epub 2010 Feb 22.

PMID:
20177021
19.

[Results of prophylactic hepatic arterial chemotherapy for liver metastases of Dukes C colorectal cancer--correlation with tumoral expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53, or orotate phosphoribosyl transferase].

Ishida H, Yamada H, Shirakawa K, Nakada H, Ohsawa T, Takeuchi I, Okada N, Yokoyama M, Inokuma S, Suzuki T, Odaka A, Hoshino T, Murata N, Hashimoto D, Itoyama S, Mori T, Matsumoto Y, Miura T.

Gan To Kagaku Ryoho. 2003 Oct;30(11):1621-6. Japanese.

PMID:
14619479
20.

CXCR4 expression predicts patient outcome and recurrence patterns after hepatic resection for colorectal liver metastases.

Yopp AC, Shia J, Butte JM, Allen PJ, Fong Y, Jarnagin WR, DeMatteo RP, D'Angelica MI.

Ann Surg Oncol. 2012 Jul;19 Suppl 3:S339-46. doi: 10.1245/s10434-011-1774-4. Epub 2011 May 17.

PMID:
21584832

Supplemental Content

Support Center